SS Innovations Showcases SSi Mantra Telesurgery Capabilities at October 2026 Conferences

SS Innovations demonstrated live robotic telesurgeries over 7,500 miles at major global conferences.

What the company is saying

SS Innovations International, Inc. is emphasizing the operational capabilities of its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console by highlighting successful live telesurgeries performed in October 2026 at two high-profile events: the EACTS Annual Meeting in Barcelona, Spain, and the SRS India Conference in New Delhi, India. The company frames these demonstrations as proof of its ability to overcome geographic barriers, with Dr. Sudhir Srivastava, Chairman and CEO, performing a cardiac procedure from Barcelona on a patient in Bengaluru, India, 7,500 miles (12,000 kilometers) away. The announcement stresses the system's technical features, such as ultra-low latency connectivity and high-definition visualization, but does not provide quantitative performance benchmarks. The company highlights that as of October 23, 2026, a total of 205 telesurgeries have been performed with the SSi Mantra system, including over 190 different types of procedures. The tone is confident and positions SS Innovations as a pioneer in telesurgery, but the release omits any discussion of commercial sales, revenue, or financial outcomes.

What the data suggests

The announcement provides concrete evidence of the SSi Mantra system's operational use, with 205 telesurgeries completed as of October 23, 2026, and clinical validation across more than 190 types of surgical procedures. The live demonstration of a cardiac procedure performed remotely over 7,500 miles at the EACTS Annual Meeting is a significant technical milestone, as are the four additional live telesurgeries at the SRS India Conference. The system's modular design, with 3 to 5 robotic arms and over 40 types of endo-surgical instruments, supports a broad range of specialties. However, the data is limited to operational and technical achievements; there are no disclosed figures on revenue, commercial adoption, sales pipeline, or financial performance. The evidence supports claims of technical feasibility and clinical deployment but does not substantiate broader commercial success or market penetration.

Analysis

The announcement is upbeat and highlights impressive operational milestones, such as 205 telesurgeries performed and successful live demonstrations at major international conferences. The majority of claims are realised and supported by specific numbers and event details, with only one forward-looking statement about 'dismantling traditional geographic barriers.' However, the tone is somewhat inflated by promotional language describing the system's engineering and potential impact, without providing technical performance data or any financial results. There is no mention of revenue, profitability, or commercial adoption, so the investment signal is capped at weak_positive per the Disclosure Completeness Rule. The gap between narrative and evidence is moderate: operational achievements are real, but the broader claims about transforming healthcare access are aspirational and not yet substantiated by commercial or financial data.

Risk flags

• ●There is no disclosure of commercial sales, revenue, or customer adoption, creating uncertainty about the company's ability to translate technical demonstrations into financial results. Without evidence of market traction, the investment case remains speculative.
• ●The announcement relies heavily on high-profile demonstrations and technical claims without providing third-party validation, peer-reviewed outcomes, or comparative benchmarks, which may limit external confidence in the system's superiority or safety.
• ●Key-person dependency is evident, as Dr. Sudhir Srivastava, the Chairman and CEO, is the primary surgeon performing the headline demonstration, raising questions about scalability and reliance on individual expertise for future showcases and adoption.

Bottom line

SS Innovations has proven the technical feasibility of its SSi Mantra robotic system for long-distance telesurgery, with 205 procedures completed and high-profile live demonstrations at major international conferences. The announcement demonstrates operational capability and clinical breadth but provides no evidence of commercial sales, revenue generation, or customer adoption. The company's narrative is credible in terms of technical achievement but aspirational regarding broader healthcare impact and market penetration. Investors should recognize that while the technology works in controlled settings, the path to commercial success remains unproven. The most important takeaway is that operational milestones have been reached, but financial and market validation are still absent; future updates should focus on sales, adoption rates, and revenue to clarify the business trajectory.

Announcement summary

(NASDAQ: SSII) SS Innovations International, Inc. announced that its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console were showcased in successful telesurgeries during October 2026 at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain, and the Society of Robotic Surgery India (SRS India) Conference in New Delhi, India. At the EACTS Annual Meeting, Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer, performed a robotic-assisted cardiac telesurgery using the SSi Mantra and SSi MantrAsana tele-surgeon console live on stage in Barcelona, approximately 7,500 miles (12,000 kilometers) from the patient at Sri Madhusudan Sai Institute of Medical Sciences and Research in Bengaluru, India. Dr. Srivastava remotely conducted a robotic atrial septal defect (ASD) procedure with patient-side support from Dr. Lalit Malik, Chief Cardiac Surgeon of Manipal Hospital Jaipur. The EACTS Annual Meeting is described as the largest global gathering of leaders in the cardiothoracic surgical community. At the inaugural SRS India Conference, four surgeons successfully completed four separate robotic-assisted telesurgeries featuring the SSi Mantra and SSi MantrAsana tele-surgeon console in live demonstrations. The procedures performed or broadcast live included a right partial nephrectomy, a right hemicolectomy, a left-sided pyeloplasty on a pediatric patient, and a modified radical hysterectomy with a sentinel lymph node biopsy. The SRS India Conference was organized by the Society of Robotic Surgery and officially inaugurated by Dr. Jitendra Singh, India’s Minister of Science and Technology. The SSi MantrAsana is engineered for real-time remote procedures through ultra-low latency connectivity, high-definition visualization, and precise instrument control. As of October 23, 2026, a total of 205 telesurgeries, including intricate cardiac procedures, have been performed with the SSi Mantra surgical robotic system. The SSi Mantra system is a modular, multi-arm system with 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for patient information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the standard surgeon command center, intended to provide equivalent control functionality with enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for pediatric and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.

Disagree with this article?